The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective σ-1 receptor PET agent 18F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (18F-FTC-146). Methods: Ten healthy volunteers (5 women, 5 men; age ± SD, 34.3 ± 6.5 y) were recruited, and written informed consent was obtained from all participants. Series of whole-body PET/MRI examinations were acquired for up to 3 h after injection (357.2 ± 48.8 MBq). Blood samples were collected, and standard vital signs (heart rate, pulse oximetry, and body temperature) were monitored at regular intervals. Regions of interest were delineated, time-activity curves were calculated, and organ uptake and dosimetry were estimated. Results: All subjects tolerated the PET/MRI examination well, and no adverse reactions to 18F-FTC-146 were reported. High accumulation of 18F-FTC-146 was observed in σ-1 receptor-dense organs such as the pancreas and spleen, moderate uptake in the brain and myocardium, and low uptake in bone and muscle. High uptake was also observed in the kidneys and bladder, indicating renal tracer clearance. The effective dose of 18F-FTC-146 was 0.0259 ± 0.0034 mSv/MBq (range, 0.0215-0.0301 mSv/MBq). Conclusion: First-in-human studies with clinical-grade 18F-FTC-146 were successful. Injection of 18F-FTC-146 is safe, and absorbed doses are acceptable. The potential of 18F-FTC-146 as an imaging agent for a variety of neuroinflammatory diseases is currently under investigation.
The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective σ-1 receptor PET agent 18F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (18F-FTC-146). Methods: Ten healthy volunteers (5 women, 5 men; age ± SD, 34.3 ± 6.5 y) were recruited, and written informed consent was obtained from all participants. Series of whole-body PET/MRI examinations were acquired for up to 3 h after injection (357.2 ± 48.8 MBq). Blood samples were collected, and standard vital signs (heart rate, pulse oximetry, and body temperature) were monitored at regular intervals. Regions of interest were delineated, time-activity curves were calculated, and organ uptake and dosimetry were estimated. Results: All subjects tolerated the PET/MRI examination well, and no adverse reactions to 18F-FTC-146 were reported. High accumulation of 18F-FTC-146 was observed in σ-1 receptor-dense organs such as the pancreas and spleen, moderate uptake in the brain and myocardium, and low uptake in bone and muscle. High uptake was also observed in the kidneys and bladder, indicating renal tracer clearance. The effective dose of 18F-FTC-146 was 0.0259 ± 0.0034 mSv/MBq (range, 0.0215-0.0301 mSv/MBq). Conclusion: First-in-human studies with clinical-grade 18F-FTC-146 were successful. Injection of 18F-FTC-146 is safe, and absorbed doses are acceptable. The potential of 18F-FTC-146 as an imaging agent for a variety of neuroinflammatory diseases is currently under investigation.
Authors: Alexander M Grant; Timothy W Deller; Mohammad Mehdi Khalighi; Sri Harsha Maramraju; Gaspar Delso; Craig S Levin Journal: Med Phys Date: 2016-05 Impact factor: 4.071
Authors: Bin Shen; Jun Hyung Park; Trine Hjørnevik; Peter W Cipriano; Daehyun Yoon; Praveen K Gulaka; Dawn Holly; Deepak Behera; Bonnie A Avery; Sanjiv S Gambhir; Christopher R McCurdy; Sandip Biswal; Frederick T Chin Journal: Mol Imaging Biol Date: 2017-10 Impact factor: 3.488
Authors: Philipp Heusch; Christian Buchbender; Karsten Beiderwellen; Felix Nensa; Verena Hartung-Knemeyer; Thomas C Lauenstein; Andreas Bockisch; Michael Forsting; Gerald Antoch; Till A Heusner Journal: Eur J Radiol Date: 2013-02-08 Impact factor: 3.528
Authors: Alba Vidal-Torres; Beatriz de la Puente; Maria Rocasalbas; Clara Touriño; Simona Andreea Bura; Begoña Fernández-Pastor; Luz Romero; Xavier Codony; Daniel Zamanillo; Helmut Buschmann; Manuel Merlos; José Manuel Baeyens; Rafael Maldonado; José Miguel Vela Journal: Eur J Pharmacol Date: 2013-04-28 Impact factor: 4.432
Authors: Michelle L James; Bin Shen; Cristina L Zavaleta; Carsten H Nielsen; Christophe Mesangeau; Pradeep K Vuppala; Carmel Chan; Bonnie A Avery; James A Fishback; Rae R Matsumoto; Sanjiv S Gambhir; Christopher R McCurdy; Frederick T Chin Journal: J Med Chem Date: 2012-09-20 Impact factor: 7.446
Authors: Francesco Spinelli; Ahmed Haider; Annamaria Toscano; Maria Laura Pati; Claudia Keller; Francesco Berardi; Nicola Antonio Colabufo; Carmen Abate; Simon M Ametamey Journal: Am J Nucl Med Mol Imaging Date: 2018-02-05
Authors: Sebastiano Intagliata; Hebaalla Agha; Theresa A Kopajtic; Jonathan L Katz; Shyam H Kamble; Abhisheak Sharma; Bonnie A Avery; Christopher R McCurdy Journal: Med Chem Res Date: 2020-07-08 Impact factor: 1.965
Authors: Daehyun Yoon; Angela M Fast; Peter Cipriano; Bin Shen; Jessa B Castillo; Christopher R McCurdy; Carina Mari Aparici; Deirdre Lum; Sandip Biswal Journal: Front Pain Res (Lausanne) Date: 2021-10-20
Authors: Antonino N Fallica; Valeria Pittalà; Maria N Modica; Loredana Salerno; Giuseppe Romeo; Agostino Marrazzo; Mohamed A Helal; Sebastiano Intagliata Journal: J Med Chem Date: 2021-06-02 Impact factor: 7.446
Authors: D L Bailey; B J Pichler; B Gückel; G Antoch; H Barthel; Z M Bhujwalla; S Biskup; S Biswal; M Bitzer; R Boellaard; R F Braren; C Brendle; K Brindle; A Chiti; C la Fougère; R Gillies; V Goh; M Goyen; M Hacker; L Heukamp; G M Knudsen; A M Krackhardt; I Law; J C Morris; K Nikolaou; J Nuyts; A A Ordonez; K Pantel; H H Quick; K Riklund; O Sabri; B Sattler; E G C Troost; M Zaiss; L Zender; Thomas Beyer Journal: Mol Imaging Biol Date: 2018-02 Impact factor: 3.488
Authors: Peter William Cipriano; Sheen-Woo Lee; Daehyun Yoon; Bin Shen; Vivianne Lily Tawfik; Catherine Mills Curtin; Jason L Dragoo; Michelle Louise James; Christopher Robert McCurdy; Frederick Te-Ning Chin; Sandip Biswal Journal: J Pain Res Date: 2018-10-12 Impact factor: 3.133
Authors: François-Xavier Lepelletier; Matthias Vandesquille; Marie-Claude Asselin; Christian Prenant; Andrew C Robinson; David M A Mann; Michael Green; Elizabeth Barnett; Samuel D Banister; Marco Mottinelli; Christophe Mesangeau; Christopher R McCurdy; Inga B Fricke; Andreas H Jacobs; Michael Kassiou; Hervé Boutin Journal: Theranostics Date: 2020-06-29 Impact factor: 11.600
Authors: Yu Lan; Ping Bai; Zude Chen; Ramesh Neelamegam; Michael S Placzek; Hao Wang; Stephanie A Fiedler; Jing Yang; Gengyang Yuan; Xiying Qu; Hayden R Schmidt; Jinchun Song; Marc D Normandin; Chongzhao Ran; Changning Wang Journal: Acta Pharm Sin B Date: 2019-07-11 Impact factor: 11.413